Tris Pharma, Inc.
24
0
0
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
4.2%
1 terminated/withdrawn out of 24 trials
95.5%
+8.9% vs industry average
42%
10 trials in Phase 3/4
33%
7 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
EEG Biomarkers for ADHD Stimulant Treatment
Role: collaborator
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
Role: lead
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
Role: lead
A Study to Assess the Abuse Potential of Intranasal Cebranopadol
Role: lead
A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD
Role: collaborator
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.
Role: lead
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
Role: lead
Assessment of Abuse Potential of Cebranopadol in Humans
Role: lead
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
Role: lead
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
Role: lead
Assessment of GRT6005 in Painful Osteoarthritis of the Knee
Role: lead
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
Role: lead
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
Role: lead
Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy
Role: lead
Bunionectomy Trial With GRT6005
Role: lead
Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.
Role: lead
CORAL XT - Open-label Extension Trial of the CORAL Trial
Role: lead
A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol
Role: lead
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
Role: lead
Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic
Role: lead